Africa first covid-19 vaccine trials

- South Africa rolls out Oxford University trials

- Country’s covid-19 cases surpass 120 000 and over 2000 deaths

South Africa, currently with the highest cases of confirmed covid-19 in the continent, at over 120 000, has become the second country outside of the United Kingdom to take part in the Oxford human trials for a potential vaccine against the novel coronavirus.

South Africa leads the continent with confirmed cases at just about half of the continent’s total cases of over 200 000. South Africa has also recorded over 2000 deaths as of last week Friday. The country’s rising covid 19 cases have also put its neighbours on high alert to avoid interborder transmissions.

Although borders have remained closed, essential goods are permitted by road, posing a threat of the spread. Most of South Africa’s neighbouring countries, including Botswana, have put in place strategies to test truckers on entry, and those testing positive are sent back to their countries.

The Oxford University trials rolled out in South Africa on Wednesday, as cases continue to rise and concerns grow over potential access to life-saving treatments, will bring hope to the continent’s most affected nation. Hopes are that South Africa’s involvement in vaccine trials will ensure the continent will have access to an affordable vaccine and not be left at the back of the queue.

The trial, conducted with local partner University of the Witwatersrand, will consist of 2,000 volunteers from 18 to 65 years of age, including some HIV positive patients, who will be monitored for 12 months after vaccination to asses how well the vaccine guards against COVID-19.

“Once 60% of the population, especially the adult population, becomes immune, we expect that effective reproductive rate to go under 1, which basically means the virus will still be around, it will still circulate, but its chain of transmission has been interrupted,” said Shabir Madhi, professor of vaccinology at Wits University and leader of the trial.

The ChAdOx1 nCoV-19 vaccine, also known as AZD1222, was originally developed by Oxford University scientists, who are now working with AstraZeneca on development and production.

There are over 4,000 participants enrolled in the UK, with enrollment of an additional 10,000 participants planned, the university said in a statement on Wednesday.

The World Health Organization (WHO) has warned Africa could be the next epicentre of the pandemic.

Trying out a new medical intervention in Africa always rings alarm bells because of a history of big pharmaceutical companies using Africans as guinea pigs.

“I feel a little bit scared, but I want to know what is going on with this vaccine so that I can tell my friends and others,” said Junior Mhlongo, a volunteer who received the vaccine at a hospital in Johannesburg.

There are currently no approved vaccines or treatments for the illness caused by the new coronavirus, but more than a dozen vaccines from more than 100 candidates globally are being tested in humans.


9 views0 comments